Ivivi Technologies, Inc announced that the previously announced results from a double-blind, randomized, placebo-controlled and prospective clinical trial on "no-option'' cardiac patients utilizing the Company's targeted pulsed electromagnetic field (tPEMF) technology have been peer reviewed and accepted for presentation at the American College of Cardiology (ACC) 58th Annual Scientific Meeting. The paper, titled "Use of Pulsed Electromagnetic Fields For Ischemic Cardiomyopathy Therapy (EFFECT Trial): A Randomized, Double-Blind, Parallel, Placebo-Controlled, Prospective Trial'' will be presented by Dr. Michael Shen Principal Investigator of the EFFECT trial. In a study of 30 patients with cardiomyopathies and no other treatment options, active treatment arm patients demonstrated significant reductions in anginal pain and improvements in physical activity. One month after commencement of treatment the results began emerging with increasing significance at three and five month intervals. The changes in the clinical outcomes were consistent with those seen in angina patients for whom standard therapeutic intervention is possible.